Cancer Family
Head and Neck Neoplasm
CI-CAN-00000021Explore in graph →
Non-malignant1,571 active trials17 approved drugs142 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000021Explore in graph →
Clinical trials
6,372 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03358472 | Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304) | completed | Phase 3 | 89 | Incyte CorporationINDUSTRY | 14 | Sep 29, 2026 | clinicaltrials |
| NCT01520701 | Impact of Applying a Bandage Skin Hydrogel on the Pains of the Head and Neck in Patients With Cancer of Head and Neck Treated With Radiotherapy(IPAC) | completed | Phase 3 | 130 | Centre Francois BaclesseOTHER | 1 |
| Sep 1, 2026 |
| clinicaltrials |
| NCT02997553 | Fluorescence for Sentinel Lymph Node Identification in Cancer Surgery(GASVERT) | completed | Phase 3 | 744 | Institut de Cancérologie de LorraineOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT03258554 | Radiation Therapy With Durvalumab or Cetuximab in Treating Patients With Locoregionally Advanced Head and Neck Cancer Who Cannot Take Cisplatin | completed | Phase 2 / Phase 3 | 196 | National Cancer Institute (NCI)NIH | 2 | Aug 27, 2026 | clinicaltrials |
| NCT00162708 | Very Intense Radiotherapy-chemotherapy Regimen in Advanced HNSCC | completed | Phase 2 / Phase 3 | 120 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT01302834 | Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer | completed | Phase 3 | 987 | Radiation Therapy Oncology GroupNETWORK | 2 | Jul 20, 2026 | clinicaltrials |
| NCT07435324 | A Comparative Study of Efficacy and Safety of RPH-002 and Erbitux® in Unresectable Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma | completed | Phase 3 | 161 | R-PharmINDUSTRY | 2 | Jul 14, 2026 | clinicaltrials |
| NCT02973386 | Prognostic Analysis of Concurrent Chemoradiotherapy With/Without Adjuvant Chemotherapy for Locally Advanced NPC Patients | completed | Phase 3 | 294 | Sun Yat-sen UniversityOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT02633202 | Concurrent Chemotherapy for the Intermediate Risk Nasopharyngeal Carcinoma In Intensity-modulated Radiotherapy Era | completed | Phase 3 | 338 | Sun Yat-sen UniversityOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT00003809 | Cisplatin With or Without Monoclonal Antibody Therapy in Treating Patients With Metastatic or Recurrent Head and Neck Cancer | completed | Phase 3 | — | Eastern Cooperative Oncology GroupNETWORK | 3 | Feb 27, 2026 | clinicaltrials |
| NCT03040999 | Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412) | completed | Phase 3 | 804 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Feb 4, 2026 | clinicaltrials |
| NCT01856478 | LUX-Head&Neck 3: Afatinib (BIBW2992) Versus Methotrexate for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer After Platinum Based Chemotherapy | completed | Phase 3 | 340 | Boehringer IngelheimINDUSTRY | 8 | Jan 12, 2026 | clinicaltrials |
| NCT04157985 | Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors | completed | Phase 3 | 161 | Dan ZandbergOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT02918955 | Definitive Chemo-Radiotherapy for Regionally Advanced Head and Neck Cancer With or Without Up-front Neck Dissection(UPFRONT-NECK) | completed | Phase 3 | 65 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT02442375 | Uniform FDG-PET Guided Gradient Dose Prescription to Reduce Late Radiation Toxicity(UPGRADE-RT) | completed | Phase 3 | 300 | Radboud University Medical CenterOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT04338399 | The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC(BURAN) | completed | Phase 3 | 487 | Adlai Nortye Biopharma Co., Ltd.INDUSTRY | 17 | Nov 17, 2025 | clinicaltrials |
| NCT00765440 | Study of Nutrition Regimens in Treating Patients With Cancer of the Upper Aerodigestive Tract | completed | Phase 3 | 311 | Centre Antoine LacassagneOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT00410761 | An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer | completed | Phase 3 | 331 | Genzyme, a Sanofi CompanyINDUSTRY | 24 | Sep 24, 2025 | clinicaltrials |
| NCT02358031 | A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/KEYNOTE-048) | completed | Phase 3 | 882 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 18, 2025 | clinicaltrials |
| NCT02908477 | Evaluation of De-escalated Adjuvant Radiation Therapy for Human Papillomavirus (HPV)-Associated Oropharynx Cancer | completed | Phase 3 | 228 | Mayo ClinicOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT03924986 | Tislelizumab Combined With Chemotherapy Versus Chemotherapy Alone in Recurrent or Metastatic Nasopharyngeal Cancer (NPC)(RATIONALE-309) | completed | Phase 3 | 263 | BeiGeneINDUSTRY | 3 | Jan 31, 2025 | clinicaltrials |
| NCT01504815 | Adaptive Radiation Treatment for Head and Neck Cancer(ARTFORCE) | completed | Phase 3 | 268 | The Netherlands Cancer InstituteOTHER | 5 | Jan 29, 2025 | clinicaltrials |
| NCT00248235 | Resistance Exercise Training for the Shoulder and Neck Following Surgery for Head and Neck Cancer | completed | Phase 2 / Phase 3 | 64 | University of AlbertaOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT05369234 | Effects of Oral Aloe Vera Juice on Chemotherapy and Radiation-induced Oral Mucositis and Esophagitis | completed | Phase 3 | 100 | Covenant Health Cancer CenterOTHER | 1 | Oct 10, 2024 | clinicaltrials |
| NCT05865548 | Addition of Aspirin to Standard of Care in Oral Cancer | completed | Phase 2 / Phase 3 | 60 | Banaras Hindu UniversityOTHER | 1 | Aug 13, 2024 | clinicaltrials |
| NCT02923258 | Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer | completed | Phase 2 / Phase 3 | 224 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityOTHER | 1 | Jun 20, 2024 | clinicaltrials |
| NCT05564286 | Triple Antiemetic Regimen for Chemoradiotherapy in Cervical Cancer or Nasopharyngeal Cancer | completed | Phase 3 | 116 | Shantou University Medical CollegeOTHER | 1 | Feb 6, 2024 | clinicaltrials |
| NCT02369835 | Modified Dakin's Solution in Reducing Radiation-Induced Dermatitis in Patients With Head and Neck Cancer Undergoing Radiation Therapy | completed | Phase 3 | 132 | Stanford UniversityOTHER | 1 | Jan 30, 2024 | clinicaltrials |
| NCT01864850 | Non Inferiority Trial of Standard RT Versus Hypofractionated Split Course in Elderly Vulnerable Patients With HNSCC(ELAN-RT) | completed | Phase 3 | 202 | Groupe Oncologie Radiotherapie Tete et CouOTHER | 2 | Sep 22, 2023 | clinicaltrials |
| NCT02741570 | Study of Nivolumab in Combination With Ipilimumab Compared to the Standard of Care (Extreme Regimen) as First Line Treatment in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck(CheckMate 651) | completed | Phase 3 | 947 | Bristol-Myers SquibbINDUSTRY | 18 | Sep 21, 2023 | clinicaltrials |
| NCT00820248 | Radiation + Cisplatin or Panitumumab in Locally Advanced Stage III or Stage IV Head and Neck Cancer | completed | Phase 3 | 320 | NCIC Clinical Trials GroupNETWORK | 1 | Aug 22, 2023 | clinicaltrials |
| NCT02611960 | Study of Pembrolizumab (MK-3475) in Platinum Pre-treated Recurrent/Metastatic Nasopharyngeal Cancer (MK-3475-122/KEYNOTE-122) | completed | Phase 3 | 233 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Jul 13, 2023 | clinicaltrials |
| NCT00047008 | Chemotherapy and Radiation Therapy With or Without Surgery in Treating Patients With Head and Neck Cancer | completed | Phase 3 | 743 | Radiation Therapy Oncology GroupNETWORK | 1 | Jul 7, 2023 | clinicaltrials |
| NCT02578641 | A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients(VANCE) | completed | Phase 3 | 330 | Tessa TherapeuticsINDUSTRY | 5 | Jun 28, 2023 | clinicaltrials |
| NCT00003592 | Methotrexate Compared With Paclitaxel in Treating Patients With Advanced Head and Neck Cancer | completed | Phase 3 | 230 | Eastern Cooperative Oncology GroupNETWORK | 2 | Jun 22, 2023 | clinicaltrials |
| NCT01321554 | A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Trial of Lenvatinib (E7080) in 131I-Refractory Differentiated Thyroid Cancer (DTC)(SELECT) | completed | Phase 3 | 392 | Eisai Inc.INDUSTRY | 23 | Jun 22, 2023 | clinicaltrials |
| NCT00054561 | Isotretinoin, Interferon Alfa, and Vitamin E in Treating Patients With Stage III or Stage IV Head and Neck Cancer | completed | Phase 3 | — | Eastern Cooperative Oncology GroupNETWORK | 5 | Jun 15, 2023 | clinicaltrials |
| NCT03370367 | Double Blind Phase III Trial of Effects of Low Dose 13-Cisretinoic Acid on Prevention of Second Primaries in Stages I-II Head and Neck Cancer | completed | Phase 3 | 189 | Eastern Cooperative Oncology GroupNETWORK | 0 | Jun 15, 2023 | clinicaltrials |
| NCT05364918 | Clinical Study On Acute Radiotherapy-Induced Oral Mucositis In Patients With Locally Advanced Head And Neck Tumors | completed | Phase 3 | 100 | Affiliated Cancer Hospital & Institute of Guangzhou Medical UniversityOTHER | 1 | Apr 24, 2023 | clinicaltrials |
| NCT02940925 | TPC vs PF as Induction Chemotherapy Combined With CCRT for Stage IVa-b Nasopharyngeal Carcinoma | completed | Phase 3 | 241 | Sun Yat-sen UniversityOTHER | 1 | Apr 12, 2023 | clinicaltrials |
| NCT05802290 | NIVolumab in Subjects With Recurrent or Metastatic Platinum-refrACTORy SCCHN(NIVACTOR) | completed | Phase 3 | 124 | Gruppo Oncologico del Nord-OvestOTHER | 1 | Apr 6, 2023 | clinicaltrials |
| NCT04189107 | Postoperative Pain, Why Still in Hospital and DAOH Following TORS for SCCUP & OSAS | completed | Phase 3 | 18 | Rigshospitalet, DenmarkOTHER | 1 | Mar 16, 2023 | clinicaltrials |
| NCT02460419 | Maintenance Capecitabine Plus Best Supportive Care Versus Best Supportive Care for Metastatic Nasopharyngeal Carcinoma | completed | Phase 3 | 104 | Sun Yat-sen UniversityOTHER | 1 | Oct 28, 2022 | clinicaltrials |
| NCT00274937 | Radiation Therapy, Amifostine, and Chemotherapy in Treating Young Patients With Newly Diagnosed Nasopharyngeal Cancer | completed | Phase 3 | 111 | Children's Oncology GroupNETWORK | 3 | Oct 25, 2022 | clinicaltrials |
| NCT02105636 | Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) | completed | Phase 3 | 361 | Bristol-Myers SquibbINDUSTRY | 15 | Oct 5, 2022 | clinicaltrials |
| NCT01265849 | Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity(IT-MATTERS) | completed | Phase 3 | 928 | CEL-SCI CorporationINDUSTRY | 23 | Aug 19, 2022 | clinicaltrials |
Data updated 10 hours agoSource updated Sep 29, 2026source: clinicaltrials